GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vonafexor   Click here for help

GtoPdb Ligand ID: 13935

Synonyms: EYP-001 | EYP001 | PLX-007 | PLX007
Compound class: Synthetic organic
Comment: Vonafexor (EYP001) is an oral farnesoid X receptor (NR1H4) agonist [2].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 95.53
Molecular weight 489.76
XLogP 2.55
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=CC(=C(C(=C1)Cl)S(=O)(=O)N2CCN(CC2)C3=CC=C4C(=C3Cl)C=C(C(=O)O)O4)Cl
Isomeric SMILES C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl
InChI InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26)
InChI Key XLGQSYUNOIJBNR-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Proposed to reverse steatohepatitis and fibrosis in non-alcoholic fatty liver disease (NAFLD) and as an adjunct to antiviral therapy in chronic Hepatitis B treatment [1,4]. Vonefexor may also be beneficial in the treatment of Alport syndrome.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03469583 Drug Drug Interaction Study for EYP001 With Entecavir Phase 1 Interventional Enyo Pharma
NCT06939816 Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) Phase 2 Interventional Enyo Pharma
NCT06425055 Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) Phase 2 Interventional Enyo Pharma
NCT03812029 Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) Phase 2 Interventional Enyo Pharma 3